Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Xellia Pharmaceuticals USA LLC
EIR
•Xellia Pharmaceuticals USA LLC•October 13, 2016

Xellia Pharmaceuticals USA LLC – FDA EIR, Oct 13, 2016

Record Details

An FDA compliance inspection was conducted at Xellia Pharmaceuticals USA LLC in Bedford, OH, from October 11-13, 2016. This follow-up inspection, performed under a modified consent decree stemming from a previous injunction against Ben Venue Laboratories (the facility's former occupant), focused on Xellia's labeling and secondary packaging operations for Vancomycin HCl for Injection, USP. The inspection did not result in an FDA-483, indicating no formal observations of objectionable conditions. However, two key discussion points were raised with company management. First, during the Operational Qualification (OQ) of the packaging line, the firm initially deviated from the written protocol for physical vial label print verification, leading to an execution error. Xellia addressed this through a corrective action, re-executing the affected OQ sections. Second, concerns were noted regarding the Performance Qualification (PPQ) protocol for the Vision System, which appeared not to adequately test "worst-case" scenarios for detecting missing vials or errors in lot numbers, identification numbers, and expiration dates. Management was advised to justify the protocol and ensure it robustly challenges the system's ability to detect all potential defects. The FDA conveyed that the final determination regarding the facility's status would be made by their management and compliance officers, with Xellia management agreeing to address the raised discussion items.

Company
Xellia Pharmaceuticals USA LLC
Inspection date
October 13, 2016
Product type
drugs
Office
Cincinnati District Office
People
  • Nicholas L. Paulin
  • Lindsey Schwierjohann (Investigator )
  • Lauren N. Smith (investigator)
View Company Profile

ID · fd03b6e7-8634-4aaa-bb44-02e26e34e0bc

Violation Codes1
21 CFR 820.198

Full citation text and observation details available on the Dashboard.

Other documents for Xellia Pharmaceuticals USA LLC
  • 483 - 2023-09-29September 29, 2023
  • 483 - 2022-12-15December 15, 2022
  • 483 - 2022-02-07February 7, 2022
  • EIR - 2020-01-31January 31, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Xellia Pharmaceuticals USA LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.